HT9402-25-Q-9301 Amend 0001.pdf
PDF 137 KB Posted
- Solicitation number
- HT9402-25-Q-9103
- Issued by
-
Defense Health Agency
About this file
This is an amendment (0001) to Request for Quote (RFQ) HT9402-25-Q-9103 issued by the Defense Health Agency on January 8, 2025. The amendment adds five newly approved drugs (NADs) to the original solicitation: Alyftrek for Cystic Fibrosis, Crenessity for Endocrine Agents, Imkeldi for Chronic Myelogenous Leukemia, Tryngolza for Antilipidemics-2, and Wezlana for Targeted Immunomodulatory Biologics (IL-23).
The amendment is part of the Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program. The document is signed by the Contracting Officer and maintains all other terms and conditions from the original solicitation. The Defense Health Agency office issuing this amendment is located at 7700 Arlington Boulevard, Suite 5101, Falls Church, Virginia.
View the file
Other files
Show all 15
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
DEFENSE HEALTH AGENCY
7700 ARLINGTON BOULEVARD, SUITE 5101
FALLS CHURCH, VIRGINIA 22042-5101
HT9402-25-Q-9103 0001
January 8, 2025
SUBJECT: Amendment to Solicitation HT9402-25-Q-9103 to add Newly Approved Drugs (NAD) to the RFQ Solicitation
1. The purpose of this amendment is to add the following NADs to RFQ HT9402-25-Q- 9103:
a. Alyftrek - Cystic Fibrosis Agents - NA
b. Crenessity - Endocrine Agents Miscellaneous - NA
c. Imkeldi - Oncological Agents - Chronic Myelogenous Leukemia
d. Tryngolza - Antilipidemics-2 – NA
e. Wezlana - Targeted Immunomodulatory Biologics - IL-23
2. All other terms and conditions remain the same.
Marsha L. Petersen Contracting Officer
| 2025-01-08T15:26:12-0600 | |
| PETERSEN.MARSHA.LISA.1021485299 |
File details come from the government source that posted it. Updated .